Sepsis Endotheliopathy Assessment Panel

Rapid detection and analysis of endothelial cells and coagulation/inflammation biomarkers in blood to diagnose and monitor sepsis

**Technology**

- **Detects endothelial cell damage**: Linked to sepsis + sepsis severity
- **Tests for blood biomarkers**: Detects inflammation/coagulation biomarkers
- **Replaces traditional ELISA reader**

**Potential Partners**
- Enzo Lifesciences
- Abbot
- Optofluidic Bioassay

**Class II Device 501(k) regulatory pathway**

**License Technology or New Startup Company**

**Commercialization Roadmap**

**Project Milestones**

<table>
<thead>
<tr>
<th>Month</th>
<th>Milestones</th>
</tr>
</thead>
<tbody>
<tr>
<td>Month 1</td>
<td>Begin endothelial cell detection</td>
</tr>
<tr>
<td>Month 2</td>
<td>Complete detection of 6 biomarkers in buffering agent</td>
</tr>
<tr>
<td>Month 3</td>
<td>Evaluate accuracy of endothelial cell detection in standard solution of cells</td>
</tr>
<tr>
<td>Month 4</td>
<td>Complete detection of 6 biomarkers using blood</td>
</tr>
<tr>
<td>Month 5</td>
<td>Test endothelial cell detection &amp; benchmark against current standard (FACS)</td>
</tr>
</tbody>
</table>

**SPEED**

- 15-minute rapid, bedside diagnostic

**Multi-Use**

- Diagnose sepsis and severity + monitor therapeutic intervention

**Portable**

- Laptop-size for use in hospital, ambulatory and long-term care facilities

**Compatible**

- Utilizes standard syringe and tubing equipment

**Cost**

- Lower equipment and operational cost compared to competition